Clinical experience with linezolid at a large academic medical center: A case series and review of the literature

Hospital Pharmacy

Volumn 45, Issue 12, 2010, Pages 916-926

  Heintz, Brett ^a,b   Halilovic, Jenana ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c School of Pharmacy   (United States)

Author keywords

antibiotic utilization; antimicrobial stewardship; hematological toxicity; linezolid, methicillin resistant Staphylococcus aureus (MRSA); thrombocytopenia; vancomycin resistant enterococci (VRE)

Indexed keywords

CREATININE; LINEZOLID;

ABDOMINAL INFECTION; ADOLESCENT; ADULT; AGED; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; BLOODSTREAM INFECTION; CHILD; CLINICAL PRACTICE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CREATININE BLOOD LEVEL; DRUG USE; ENTEROCOCCAL INFECTION; FEMALE; HUMAN; INFANT; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NAUSEA; PNEUMONIA; PRESCHOOL CHILD; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; RISK FACTOR; SCHOOL CHILD; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

EID: 78650148204     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4512-916     Document Type: Article

References (93)

1. Boucher HW, Corey GR. Epidemiology of methicillin-re-sistant Staphylococcus aureus. Clin Infect Dis. 2008;46(Suppl 5): S344-349.
2. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32(Suppl 2): S114-132.
3. Doern GV, Jones RN, Pfaller MA, Kugler KC, Beach ML. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). Diagn Microbiol Infect Dis. 1999;34(1):65-72.
4. Rice LB. Emergence of vancomycin-resistant enterococci. Emerg Infect Dis. 2001;7(2):183-187.
5. Rice LB. Antimicrobial resistance in gram-positive bacteria. Am J Med. 2006;119(6 Suppl 1):S11-19; discussion S62-70.
6. Richards MJ EJ, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol. 2000;21: 510-515.
7. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(Suppl 5):S378-385.
8. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(Suppl 5): S368-377.
9. Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clin Proc. 2006;81(4):529-536.
10. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32(Suppl 2): S133-145.
11. Rice LB. Antimicrobial resistance in gram-positive bacteria. Am J Infect Control. 2006;34(5 Suppl 1):S11-19; discussion S64-73.
12. Sakoulas G, Moellering RC, Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis. 2008;46(Suppl 5):S360-367.
13. Shorr AF. Epidemiology of staphylococcal resistance. Clin Infect Dis. 2007;45(Suppl 3):S171-176.
14. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother. 2003;51(Suppl 2): ii9-16.
15. Paladino JA. Linezolid: an oxazolidinone antimicrobial agent. Am J Health Syst Pharm. 2002;59(24):2413-2425.
16. Wilcox MH. Update on linezolid: the first oxazolidinone antibiotic. Expert Opin Pharmacother. 2005;6(13):2315-2326.
17. Aksoy DY, Unal S. New antimicrobial agents for the treatment of gram-positive bacterial infections. Clin Microbiol Infect. 2008;14(5):411-420.
18. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother. 2003; 51(Suppl 2):ii17-25.
19. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharma-cokinet. 2003;42(13):1129-1140.
20. Vardakas KZ, Ntziora F, Falagas ME. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother. 2007;8(14):2381-2400.
21. Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Phar-macotherapy. 2007;27(2):227-249.
22. Scheetz MH, Qi C, Noskin GA, et al. The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci. Diagn Microbiol Infect Dis. 2006;56(4): 407-413.
23. Zyvox (linezolid) [package insert]. New York: Pfizer; 2008.
24. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother. 2004; 53(2):335-344.
25. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46(8):2723-2726.
26. Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003;47(6):1824-1831.
27. Attassi K, Hershberger E, Alam R, Zervos MJ. Throm-bocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34(5):695-698.
28. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36(2): 159-168.
29. Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother. 2006;50(4):1599-1602.
30. Chen YS, Lee SC, Kim WJ. Efficacy and tolerability of linezolid in treating severe skin and soft tissue infections caused by Gram-positive pathogens. J Formos Med Assoc. 2004;103(5):349-354.
31. Nasraway SA, Shorr AF, Kuter DJ, O'Grady N, Le VH, Cammarata SK. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis. 2003;37(12):1609-1616.
32. Orrick JJ, Johns T, Janelle J, Ramphal R. Thrombocyto-penia secondary to linezolid administration: what is the risk? Clin Infect Dis. 2002;35(3):348-349.
33. Senneville E, Legout L, Valette M, et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother. 2004;54(4):798-802.
34. Smith PF, Birmingham MC, Noskin GA, et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant gram-positive infections in cancer patients with neutropenia. Ann Oncol. 2003;14(5):795-801.
35. Grau S, Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Alvarez-Lerma F. Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia. J Antimicrob Chemother. 2005;56(2):440-441.
36. Babcock HM FV. Clinical experience with linezolid: a case series of 53 patients. Infect Dis Clin Pract. 2002;11:198-204.
37. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oe-sophageal varices. Br J Surg. 1973;60(8):646-649.
38. Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48(2):203-212.
39. Falagas ME, Siempos, II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis. 2008;8(1):53-66.
40. Jantausch BA, Deville J, Adler S, et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatr Infect Dis J. 2003;22(9 Suppl):S164-171.
41. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005; 41(10):1407-1415.
42. Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J. 2003;22(8):677-686.
43. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis. 2004;38(1):17-24.
44. Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis. 2007;59(2):173-179.
45. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32(3):402-412.
46. San Pedro GSCS, Oliphant TH, Todisco T. Linezolid Community-Acquired Pneumonia Study Group. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis. 2002;34:720-728.
47. Sharpe JN, Shively EH, Polk Jr HC Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant. Staphylo-coccus aureus. Am J Surg. 2005;189(4):425-428.
48. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother. 2005;56(5):923-929.
49. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34(11):1481-1490.
50. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49(6):2260-2266.
51. Wible K, Tregnaghi M, Bruss J, Fleishaker D, Naberhuis-Stehouwer S, Hilty M. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr Infect Dis J. 2003;22(4):315-323.
52. Wilcox MH. Efficacy of linezolid versus comparator therapies in gram-positive infections. J Antimicrob Chemother. 2003;51(Suppl 2):ii27-35.
53. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003;124(5):1789-1797.
54. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Line-zolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58(2):273-280.
55. Mancino P, Ucciferri C, Falasca K, Pizzigallo E, Vecchiet J. Methicillin-resistant Staphylococcus epidermidis (MRSE) endocarditis treated with linezolid. Scand J Infect Dis. 2008; 40(1):67-73.
56. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother. 2007;41(2):296-308.
57. Rao N, Ziran BH, Hall RA, Santa ER. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res. 2004;(427):67-71.
58. Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL. Similar hematologic effects of long-term linezolid and vanco-mycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis. 2004;38(8):1058-1064.
59. Steinmetz MP, Vogelbaum MA, De Georgia MA, Andrefsky JC, Isada C. Successful treatment of vancomycin-resistant en-terococcus meningitis with linezolid: case report and review of the literature. Crit Care Med. 2001;29(12):2383-2385.
60. Ntziora F, Falagas ME. Linezolid for the treatment of patients with [corrected] mycobacterial infections [corrected] a systematic review. Int J Tuberc Lung Dis. 2007;11(6):606-611.
61. Sood R, Bhadauriya T, Rao M, et al. Antimycobacterial activities of oxazolidinones: a review. Infect Disord Drug Targets. 2006;6(4):343-354.
62. Cepeda JA, Whitehouse T, Cooper B, et al. Linezolid versus teicoplanin in the treatment of gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother. 2004;53(2):345-355.
63. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42(5): 597-607.
64. Meissner HC, Townsend T, Wenman W, et al. Hemato-logic effects of linezolid in young children. Pediatr Infect Dis J. 2003;22(9 Suppl):S186-192.
65. Saiman L, Goldfarb J, Kaplan SA, et al. Safety and toler-ability of linezolid in children. Pediatr Infect Dis J. 2003;22 (9 Suppl):S193-200.
66. Yogev R, Patterson LE, Kaplan SL, et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J. 2003;22(9 Suppl):S172-177.
67. Segal JB, Moliterno AR. Platelet counts differ by sex, ethnicity, and age in the United States. Ann Epidemiol. 2006; 16(2):123-130.
68. Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol Res. 2007;55(2):81-95.
69. Martin CM. Gender-specific pharmacology: implications for therapy. Consult Pharm. 2006;21(8):620-622, 631-624.
70. Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt). 2005;14(1):19-29.
71. Chen ML. Confounding factors for sex differences in pharmacokinetics and pharmacodynamics: focus on dosing regimen, dosage form, and formulation. Clin Pharmacol Ther. 2005;78(4):322-329.
72. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499-523.
73. Gochfeld M. Framework for gender differences in human and animal toxicology. Environ Res. 2007;104(1):4-21.
74. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270(1): 414-423.
75. French G. Safety and tolerability of linezolid. J Antimicrob Chemother. 2003;51(Suppl 2):ii45-53.
76. Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28(4):345-351.
77. Mateu de Antonio J, Grau S, Morales-Molina JA, Marin-Casino M., author reply 1501.Thrombocytopenia and anemia associated with linezolid in patients with kidney failure. Clin Infect Dis. 2006;42(10):1500.
78. Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006; 42(1):66-72.
79. Soriano A, Ortega M, Garcia S, et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother. 2007;51(7):2559-2563.
80. Matsumoto K, Takeda Y, Takeshita A, et al. Renal function as a predictor of linezolid-induced thrombocytopenia. Int J Antimicrob Agents. 2009;33(1):98-99.
81. Micromedex Healthcare Series-DRUGDEX System-2008. Greenwood Village, CO: Thomson Micromedex.
82. Tsuji Y, Hiraki Y, Mizoguchi A, et al. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother. 2008;14(2):156-160.
83. Aissaoui Y, Benkabbou A, Alilou M, et al. [Thrombocy-topenia in a surgical intensive care unit: incidence, risk factors and effect on outcome]. Presse Med. 2007;36(1 Pt 1):43-49.
84. Baughman RP, Lower EE, Flessa HC, Tollerud DJ. Thrombocytopenia in the intensive care unit. Chest. 1993; 104(4):1243-1247.
85. Cawley MJ, Wittbrodt ET, Boyce EG, Skaar DJ. Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy. 1999;19(1):108-113.
86. Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med. 2002;30(8):1765-1771.
87. Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocyto-penia. Ann Pharmacother. 2003;37(4):517-520.
88. Dawson MA, Davis A, Elliott P, Cole-Sinclair M. Line-zolid-induced dyserythropoiesis: chloramphenicol toxicity revisited. Intern Med J. 2005;35(10):626-628.
89. Grim SA, Rene L, Gupta S, Clark NM. Safety of linezolid in patients with baseline thrombocytopenia. J Antimicrob Chemother. 2008;62(4):850-851.
90. Waldrep TW, Skiest DJ. Linezolid-induced anemia and thrombocytopenia. Pharmacotherapy. 2002;22(1):109-112.
91. Plachouras D, Giannitsioti E, Athanassia S, et al. No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis. 2006;43(9): e89-91.
92. Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-asso-ciated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother. 2004;54(4): 832-835.
93. Youssef S, Hachem R, Chemaly RF, et al. The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer. J Antimicrob Chemother. 2008;61(2):421-424.